Robust Stratification of Breast Cancer Subtypes Using Differential Patterns of Transcript Isoform Expression

Overview

Journal PLoS Genet

Specialty Genetics

Date 2017 Mar 7

PMID 28263985

Citations 40

Authors

Thomas P Stricker

Christopher D Brown

Chaitanya Bandlamudi

Megan McNerney

Ralf Kittler

Vanessa Montoya

April Peterson

Robert Grossman

Kevin P White

Affiliations

Soon will be listed here.

Abstract

Breast cancer, the second leading cause of cancer death of women worldwide, is a heterogenous disease with multiple different subtypes. These subtypes carry important implications for prognosis and therapy. Interestingly, it is known that these different subtypes not only have different biological behaviors, but also have distinct gene expression profiles. However, it has not been rigorously explored whether particular transcriptional isoforms are also differentially expressed among breast cancer subtypes, or whether transcript isoforms from the same sets of genes can be used to differentiate subtypes. To address these questions, we analyzed the patterns of transcript isoform expression using a small set of RNA-sequencing data for eleven Estrogen Receptor positive (ER+) subtype and fourteen triple negative (TN) subtype tumors. We identified specific sets of isoforms that distinguish these tumor subtypes with higher fidelity than standard mRNA expression profiles. We found that alternate promoter usage, alternative splicing, and alternate 3'UTR usage are differentially regulated in breast cancer subtypes. Profiling of isoform expression in a second, independent cohort of 68 tumors confirmed that expression of splice isoforms differentiates breast cancer subtypes. Furthermore, analysis of RNAseq data from 594 cases from the TCGA cohort confirmed the ability of isoform usage to distinguish breast cancer subtypes. Also using our expression data, we identified several RNA processing factors that were differentially expressed between tumor subtypes and/or regulated by estrogen receptor, including YBX1, YBX2, MAGOH, MAGOHB, and PCBP2. RNAi knock-down of these RNA processing factors in MCF7 cells altered isoform expression. These results indicate that global dysregulation of splicing in breast cancer occurs in a subtype-specific and reproducible manner and is driven by specific differentially expressed RNA processing factors.

Citing Articles

Isoform-Level Transcriptome Analysis of Peripheral Blood Mononuclear Cells from Breast Cancer Patients Identifies a Disease-Associated Isoform.

celesnik H, Gorenjak M, Krusic M, Crnobrnja B, Sobocan M, Takac I Cancers (Basel). 2024; 16(18).

PMID: 39335143 PMC: 11429621. DOI: 10.3390/cancers16183171.

SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1.

Deng L, Liao L, Zhang Y, Yang S, Hu S, Andriani L Sci Adv. 2024; 10(14):eadj4009.

PMID: 38569025 PMC: 10990288. DOI: 10.1126/sciadv.adj4009.

Xiao F, Long Z, Guo Y, Zhu H, Zhang Z, Xiao Y Aging (Albany NY). 2023; 15(12):5713-5733.

PMID: 37390121 PMC: 10333088. DOI: 10.18632/aging.204823.

The paralogues MAGOH and MAGOHB are oncogenic factors in high-grade gliomas and safeguard the splicing of cell division and cell cycle genes.

Barreiro R, Guardia G, Meliso F, Lei X, Li W, Savio A RNA Biol. 2023; 20(1):311-322.

PMID: 37294214 PMC: 10259345. DOI: 10.1080/15476286.2023.2221511.

High expression of RTN4IP1 predicts adverse prognosis for patients with breast cancer.

Wang X, Li X, Jiang W Transl Cancer Res. 2023; 12(4):859-872.

PMID: 37180657 PMC: 10174766. DOI: 10.21037/tcr-22-2350.

References

Gold B, Kirchhoff T, Stefanov S, Lautenberger J, Viale A, Garber J . Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A. 2008; 105(11):4340-5. PMC: 2393811. DOI: 10.1073/pnas.0800441105. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Shapiro I, Cheng A, Flytzanis N, Balsamo M, Condeelis J, Oktay M . An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet. 2011; 7(8):e1002218. PMC: 3158048. DOI: 10.1371/journal.pgen.1002218. View

Logette E, Wotawa A, Solier S, Desoche L, Solary E, Corcos L . The human caspase-2 gene: alternative promoters, pre-mRNA splicing and AUG usage direct isoform-specific expression. Oncogene. 2003; 22(6):935-46. DOI: 10.1038/sj.onc.1206172. View

Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I . Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1659-72. DOI: 10.1056/NEJMoa052306. View

Weinberg F, Hamanaka R, Wheaton W, Weinberg S, Joseph J, Lopez M . Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A. 2010; 107(19):8788-93. PMC: 2889315. DOI: 10.1073/pnas.1003428107. View

Parker J, Mullins M, Cheang M, Leung S, Voduc D, Vickery T . Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27(8):1160-7. PMC: 2667820. DOI: 10.1200/JCO.2008.18.1370. View

Marioni J, Mason C, Mane S, Stephens M, Gilad Y . RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res. 2008; 18(9):1509-17. PMC: 2527709. DOI: 10.1101/gr.079558.108. View

Kaplan H, Malmgren J . Impact of triple negative phenotype on breast cancer prognosis. Breast J. 2008; 14(5):456-63. DOI: 10.1111/j.1524-4741.2008.00622.x. View

10.

Mortazavi A, Williams B, McCue K, Schaeffer L, Wold B . Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008; 5(7):621-8. DOI: 10.1038/nmeth.1226. View

11.

Fushimi K, Ray P, Kar A, Wang L, Sutherland L, Wu J . Up-regulation of the proapoptotic caspase 2 splicing isoform by a candidate tumor suppressor, RBM5. Proc Natl Acad Sci U S A. 2008; 105(41):15708-13. PMC: 2572934. DOI: 10.1073/pnas.0805569105. View

12.

Trapnell C, Pachter L, Salzberg S . TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009; 25(9):1105-11. PMC: 2672628. DOI: 10.1093/bioinformatics/btp120. View

13.

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

14.

Goehe R, Shultz J, Murudkar C, Usanovic S, Lamour N, Massey D . hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 pre-mRNA processing. J Clin Invest. 2010; 120(11):3923-39. PMC: 2964989. DOI: 10.1172/JCI43552. View

15.

Romond E, Perez E, Bryant J, Suman V, Geyer Jr C, Davidson N . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1673-84. DOI: 10.1056/NEJMoa052122. View

16.

Okumura N, Yoshida H, Kitagishi Y, Nishimura Y, Matsuda S . Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer. Biochem Biophys Res Commun. 2011; 413(3):395-9. DOI: 10.1016/j.bbrc.2011.08.098. View

17.

Sablina A, Chen W, Arroyo J, Corral L, Hector M, Bulmer S . The tumor suppressor PP2A Abeta regulates the RalA GTPase. Cell. 2007; 129(5):969-82. PMC: 1945132. DOI: 10.1016/j.cell.2007.03.047. View

18.

Trapnell C, Williams B, Pertea G, Mortazavi A, Kwan G, van Baren M . Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010; 28(5):511-5. PMC: 3146043. DOI: 10.1038/nbt.1621. View

19.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14):8418-23. PMC: 166244. DOI: 10.1073/pnas.0932692100. View

20.

Hua S, Kittler R, White K . Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell. 2009; 137(7):1259-71. PMC: 3374131. DOI: 10.1016/j.cell.2009.04.043. View